Epidemiology Investigation
Dynamic monitoring of anti-poliovirus neutralizing antibody and anti-hepatitis A virus IgG antibody in healthy children immunized with inactivated enterovirus 71 vaccine (human diploid cell)
Jing Li, Yan Liang, Hongming Lin, Zhaoyong Zhang, Yanchun Che, Yun Liao, Jifu Sheng, Zhimei Zhao, Pingfang Cui, Runxiang Long, Qihan Li
Published 2017-04-30
Cite as Chin J Microbiol Immunol, 2017, 37(4): 290-296. DOI: 10.3760/cma.j.issn.0254-5101.2017.04.010
Abstract
ObjectiveTo investigate the dynamic changes of three types of anti-poliovirus neutralizing antibodies and anti-hepatitis A virus (HAV) IgG antibody in children who were immunized with inactivated enterovirus 71 (EV71) vaccine (human diploid cell).
MethodsSerum samples were collected from the subjects immunized with inactivated EV71 vaccine. Neutralizing antibodies against EV71 and poliovirus were detected by micro-cytopathic effect neutralization test. Enzyme linked immunosorbent assay (ELISA) was used to detect IgG antibody against HAV.
ResultsThe geometric mean titers (GMTs) of anti-EV71 neutralizing antibody increased to 4.85 following the first-dose injection of inactivated EV71 vaccine. A significant increase of GMTs (up to 64.37) could be observed 28 days after the second-dose vaccination. Meanwhile, results of the dynamic monitor showed that there were slight fluctuations in the neutralizing antibodies against three types of poliovirus on day 28 (28 days after the first-dose vaccination) compared with those on day 0 (before vaccination) (P<0.05); types Ⅰ and Ⅲ anti-poliovirus neutralizing antibodies on day 56 (28 days after the second-dose vaccination) remained slightly different from those on day 0 (P<0.05), but type Ⅱ anti-poliovirus neutralizing antibody on day 56 had restored to normal level (P>0.05). The level of anti-HAV IgG antibody was stable and no significant difference was found during the observation period (P>0.05).
ConclusionThis study shows that inactivated EV71 vaccine has no impact on anti-HAV IgG antibody in Children during the two-dose vaccination and in anti-EV71 antibody-producing period, but has slight influence on the anti-poliovirus antibodies. In general, changes in antibody profile do not affect the clinical efficacy of immune response.
Key words:
Inactivated enterovirus 71 vaccine (human diploid cell); Vaccinated children; Antibody; Dynamic monitor
Contributor Information
Jing Li
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
Yan Liang
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
Hongming Lin
Inner Mongolia Arong Banner Center for Disease Control and Prevention, Arong Banner 162750, China
Zhaoyong Zhang
Inner Mongolia Arong Banner Center for Disease Control and Prevention, Arong Banner 162750, China
Yanchun Che
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
Yun Liao
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
Jifu Sheng
Inner Mongolia Arong Banner Center for Disease Control and Prevention, Arong Banner 162750, China
Zhimei Zhao
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
Pingfang Cui
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
Runxiang Long
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
Qihan Li
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
